IOVA
What one share of Iovance Biotherapeutics holds
Biological Products, (No Diagnostic Substances)
We are a commercial-stage biopharmaceutical company pioneering a transformational approach to treating cancer. Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers.
Iovance Biotherapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.79 |
|---|---|
| Profit | −$0.71 |
| Capex (buildings and equipment) | $0.08 |
| Free cash flow | −$0.72 |
| Cash and investments | $0.24 |
| Book value | $1.62 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2011 | — | −$33.80 | $0.04 | −$8.20 | — | −$16.40 |
| 2012 | — | −$4.10 | $0.00 | −$2.80 | — | −$13.80 |
| 2013 | — | −$3.47 | $0.00 | −$0.38 | — | — |
| 2014 | — | −$0.48 | $0.06 | $0.28 | — | $1.33 |
| 2015 | — | −$0.62 | $0.03 | −$0.44 | — | $2.14 |
| 2016 | — | −$1.85 | $0.03 | −$0.62 | — | $2.68 |
| 2017 | — | −$1.41 | $0.02 | −$1.22 | — | $1.99 |
| 2018 | — | −$1.27 | $0.01 | −$1.05 | — | $3.78 |
| 2019 | — | −$1.59 | $0.06 | −$1.33 | — | $2.37 |
| 2020 | — | −$1.88 | $0.34 | −$1.82 | — | $4.44 |
| 2021 | — | −$2.23 | $0.24 | −$1.73 | — | $3.96 |
| 2022 | — | −$2.49 | $0.13 | −$1.97 | — | $2.66 |
| 2023 | — | −$1.89 | $0.09 | −$1.63 | — | $2.28 |
| 2024 | $0.57 | −$1.28 | $0.04 | −$1.26 | — | $2.33 |
| 2025 | $0.74 | −$1.09 | $0.09 | −$0.94 | — | $1.70 |